What's in yuanli Zhao's pipeline?

yuanli Zhao has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with yuanli Zhao's portfolio?

Top competitors by shared drug class: Guangzhou Yipinhong Pharmaceutical CO.,LTD, Hvidovre University Hospital, United States Naval Medical Center, San Diego.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yuanli-zhao.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

yuanli Zhao — Portfolio Competitive Intelligence Brief

yuanli Zhao pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
dl-3-n-butylphthalide (NBP)	dl-3-n-butylphthalide (NBP)	phase 3	vasodilator		Cerebrovascular Disease

Therapeutic area mix

Cerebrovascular Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 shared drug class
Hvidovre University Hospital · 1 shared drug class
United States Naval Medical Center, San Diego · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for yuanli Zhao:

Cite this brief

Drug Landscape (2026). yuanli Zhao — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yuanli-zhao. Accessed 2026-05-16.